Group 1: Company Performance - Bristol Myers Squibb (BMY) ended the recent trading session at $56.81, showing a -0.58% change from the previous day's closing price, which lagged behind the S&P 500's daily gain of 0.16% [1] - Over the past month, shares of Bristol Myers Squibb gained 0.28%, outperforming the Medical sector's loss of 5.31% and the S&P 500's loss of 2.7% [1] Group 2: Upcoming Earnings - The company's earnings report is scheduled for February 6, 2025, with analysts expecting earnings of $1.46 per share, indicating a year-over-year decline of 14.12% [2] - The Zacks Consensus Estimate for revenue projects net sales of $11.6 billion, reflecting a 1.05% increase from the year-ago period [2] Group 3: Analyst Estimates and Rankings - Recent changes to analyst estimates for Bristol Myers Squibb are important as they reflect the shifting dynamics of short-term business patterns [3] - The Zacks Rank system, which includes estimate changes, currently ranks Bristol Myers Squibb at 2 (Buy), with a 0.29% rise in the Zacks Consensus EPS estimate over the past month [5] Group 4: Valuation Metrics - Bristol Myers Squibb is trading at a Forward P/E ratio of 7.9, which is a discount compared to the industry average Forward P/E of 22.58 [6] - The company has a PEG ratio of 1.98, compared to the Medical - Biomedical and Genetics industry's average PEG ratio of 1.5 [6] Group 5: Industry Overview - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 64, placing it in the top 26% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

It was a good year for biotech giant Bristol Myers (BMY) . Shares of the company have risen 11.4% against the industry’s 15.6% decline. The stock has also outperformed the sector but underperformed the S&P 500 during this period.The outperformance was more pronounced in the second half of the year, buoyed by strong quarterly performances, an increase in annual guidance and approval of new drugs.This stupendous rally after touching a 52-week low in July has enabled BMY to regain its lost territories. The sto ...

Group 1 - The marketplace channel Haggerston BioHealth offers exclusive stock tips focused on Pharma, Biotech, and Healthcare, providing access to investment bank-grade financial models and research [1] - The group caters to both novice and experienced biotech investors, offering insights on catalysts, buy and sell ratings, product sales forecasts, and integrated financial statements [2] - The analyst has extensive experience in the biotech sector, having covered over 1,000 companies and leading the investing group Haggerston BioHealth [3]

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use tried-and-true metrics and fundamental ...

Core Insights - The European Commission has approved the combination of Opdivo and Yervoy for the first-line treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC) [1][20][14] - This approval is based on data from the phase III CheckMate -8HW study, which demonstrated a significant improvement in progression-free survival (PFS) and reduced the risk of disease progression or death by 79% compared to chemotherapy [12][7] - Opdivo, a key growth driver for Bristol Myers Squibb (BMY), generated global sales of $6.8 billion in the first nine months of the year, and the expansion of its label is expected to further boost sales [16][20] Approval and Study Data - The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of Opdivo plus Yervoy in November [6] - The latest approval makes Opdivo plus Yervoy the first dual checkpoint inhibitor therapy approved for first-line treatment of MSI-H/dMMR mCRC in the EU [14] - The safety profile of the combination therapy was consistent with previously reported data, showing no new safety signals [22] Other Developments - Bristol Myers also announced positive top-line data from two phase III studies evaluating Sotyktu (deucravacitinib) for treating adults with active psoriatic arthritis (PsA), with significant improvements in disease activity observed [3][17] - Sotyktu is already approved in several countries for treating moderate-to-severe plaque psoriasis [24]

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

About five months ago, I wrote my last article about Bristol-Myers Squibb Company (NYSE: BMY ). And after being a bit more cautious in my previous article, I clearly argued that the stock was a “Buy” at this point and a bargain. InMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitaliza ...

Bristol Myers Squibb (BMY) closed the latest trading day at $56.30, indicating a -0.95% change from the previous session's end. The stock fell short of the S&P 500, which registered a loss of 0.09% for the day. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, lost 0.1%.Heading into today, shares of the biopharmaceutical company had lost 1.8% over the past month, outpacing the Medical sector's loss of 2.1% and lagging the S&P 500's loss of 0.29% in that time.Investors will be eagerly watc ...

If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there are many other stocks out there that pay much higher than that -- and they aren't risky investments to hold in your portfolio.For retirees, three blue chip stocks that can be ideal options for your portfolio include Bristol Myers Squibb (BMY -0.56%), Enbridge (ENB 0.40%), and Coca-Cola (KO -0.35%). These divid ...

One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power. A person who starts out even with a relatively modest sum, like $250, then progressively (and consistently) invests more over time, and stays invested for the long term, will typically see their efforts yield significant returns -- provided they choose the right companies to buy.But which ones are the "right" ones to invest in? Let's consider two compan ...